TWI711464B - 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法 - Google Patents

預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法 Download PDF

Info

Publication number
TWI711464B
TWI711464B TW105110295A TW105110295A TWI711464B TW I711464 B TWI711464 B TW I711464B TW 105110295 A TW105110295 A TW 105110295A TW 105110295 A TW105110295 A TW 105110295A TW I711464 B TWI711464 B TW I711464B
Authority
TW
Taiwan
Prior art keywords
liver
mannitol
fatty liver
combination
sucralose
Prior art date
Application number
TW105110295A
Other languages
English (en)
Chinese (zh)
Other versions
TW201718015A (zh
Inventor
胡幼圃
何欣恬
吳永恩
唐熙卉
Original Assignee
欣耀生醫股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 欣耀生醫股份有限公司 filed Critical 欣耀生醫股份有限公司
Publication of TW201718015A publication Critical patent/TW201718015A/zh
Application granted granted Critical
Publication of TWI711464B publication Critical patent/TWI711464B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/733—Compounds of undetermined constitution obtained from animals or plants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
TW105110295A 2015-11-19 2016-03-31 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法 TWI711464B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257697P 2015-11-19 2015-11-19
US62/257,697 2015-11-19

Publications (2)

Publication Number Publication Date
TW201718015A TW201718015A (zh) 2017-06-01
TWI711464B true TWI711464B (zh) 2020-12-01

Family

ID=58718029

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105110295A TWI711464B (zh) 2015-11-19 2016-03-31 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法

Country Status (7)

Country Link
US (1) US10925854B2 (https=)
EP (1) EP3391881A4 (https=)
JP (4) JP2018534323A (https=)
CN (2) CN107613968A (https=)
HK (1) HK1244213A1 (https=)
TW (1) TWI711464B (https=)
WO (1) WO2017084234A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890810A1 (ru) * 2015-09-24 2018-11-30 Синью Фарма Инк. Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
CN110151787A (zh) * 2018-02-12 2019-08-23 玛旺干细胞医学生物科技股份有限公司 护肝组合物及其用途
TWI691719B (zh) * 2018-10-19 2020-04-21 香港商阿瓦隆 海帕波有限公司 半乳糖快速定量檢測系統及其應用
US20220265603A1 (en) * 2019-06-25 2022-08-25 National Hospital Organization Hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin
CN112471376A (zh) * 2020-11-02 2021-03-12 辽宁康汇医学临床研究有限公司 一种防治酒精性脂肪肝的固体饮料及其制备方法
CN113440514B (zh) * 2021-08-20 2022-09-09 中国农业科学院郑州果树研究所 含橙皮素的组合物及其制备降血糖药物的应用
CN117205159A (zh) * 2023-09-04 2023-12-12 中国医学科学院药用植物研究所 一种自纳米组合物及制备方法与应用
CN119184297A (zh) * 2024-09-18 2024-12-27 中国农业大学 葛根素及其衍生物调控des1改善肝脏脂质堆积及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140038921A1 (en) * 2011-04-20 2014-02-06 National Defense Education And Research Foundation New low side effect pharmaceutical composition containing antituberculosis drugs
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4388328A (en) * 1981-10-15 1983-06-14 Warner-Lambert Company Sorbitol containing mixture encapsulated flavor
US5080910A (en) * 1990-05-15 1992-01-14 Werner-Lambert Company Stabilized chlorodeoxysugar sweetening agents in powder form and methods for preparing same
US5804165A (en) * 1996-07-24 1998-09-08 Arnold; Michael J. Antiplaque oral composition
EP1072264A4 (en) * 1998-04-16 2004-07-28 Ajinomoto Kk MEDICINES FOR THE PRIMARY BILE CIRCLES
JP4824886B2 (ja) * 2001-09-11 2011-11-30 長岡香料株式会社 フルクトース吸収阻害剤、組成物、および食品
JP4203282B2 (ja) * 2002-08-26 2008-12-24 株式会社青粒 アブラナ科植物の抽出物とその用途
US20060276432A1 (en) * 2003-04-03 2006-12-07 Kazuyuki Oku Lipid-regulating agent and use thereof
JPWO2006135084A1 (ja) * 2005-06-14 2009-01-08 学校法人 久留米大学 脂肪性肝炎または脂肪肝の予防または治療薬
JP2007182405A (ja) * 2006-01-10 2007-07-19 Univ Kurume 脂肪性肝疾患の改善治療薬
JPWO2009028457A1 (ja) * 2007-08-29 2010-12-02 国立大学法人信州大学 非アルコール性脂肪肝炎治療薬
CN101683351B (zh) * 2008-09-24 2011-09-07 汪鋆植 根皮苷在制备保肝药物或保健食品中的用途
CN101744865B (zh) * 2008-12-18 2012-07-25 山东福田药业有限公司 一种木糖醇护肝片的制备方法
KR20120008034A (ko) * 2009-03-17 2012-01-25 엡탈리스 파마 캐나다 아이엔씨. 우르소데옥시콜산의 증가된 투여량으로 비알콜성 지방간염을 치료하는 방법
TR200904862A1 (tr) * 2009-05-29 2010-12-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Sukraloz formülasyonu ve üretim prosesi
CN101933900A (zh) * 2009-07-02 2011-01-05 天津瑞普生物技术股份有限公司 一种用于防治禽类肝病的复方制剂及其制备方法
JP2011231078A (ja) * 2010-04-30 2011-11-17 Nagaoka Koryo Kk 非アルコール性脂肪性肝疾患の予防および／または治療に有効な経口摂取用組成物
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
CN102908596B (zh) * 2011-08-05 2014-09-03 成都永康制药有限公司 一种治疗脂肪肝的中药组合物
US9675699B2 (en) * 2011-12-22 2017-06-13 International Flavors & Fragrances Inc. Cooling enhancing compositions
US20140274979A1 (en) * 2013-03-13 2014-09-18 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
US10441560B2 (en) * 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP6194412B2 (ja) * 2013-04-29 2017-09-06 ハーシャ チグルパティ アルコール飲料の毒性低減
CN103432528A (zh) * 2013-08-23 2013-12-11 冯庄明 一种治疗非酒精性脂肪肝的中药制剂
EA201890810A1 (ru) * 2015-09-24 2018-11-30 Синью Фарма Инк. Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140038921A1 (en) * 2011-04-20 2014-02-06 National Defense Education And Research Foundation New low side effect pharmaceutical composition containing antituberculosis drugs
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合

Also Published As

Publication number Publication date
JP2021105037A (ja) 2021-07-26
CN116440143A (zh) 2023-07-18
HK1244213A1 (zh) 2018-08-03
EP3391881A1 (en) 2018-10-24
CN107613968A (zh) 2018-01-19
TW201718015A (zh) 2017-06-01
JP2023145714A (ja) 2023-10-11
JP2025124769A (ja) 2025-08-26
US20180117003A1 (en) 2018-05-03
WO2017084234A1 (zh) 2017-05-26
JP7690526B2 (ja) 2025-06-10
EP3391881A4 (en) 2020-03-11
US10925854B2 (en) 2021-02-23
JP2018534323A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
TWI711464B (zh) 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法
Cao et al. Quercetin ameliorates nonalcoholic fatty liver disease (NAFLD) via the promotion of AMPK-mediated hepatic mitophagy
Yang et al. Maresin1 protect against ferroptosis-induced liver injury through ROS inhibition and Nrf2/HO-1/GPX4 activation
Li et al. Fenretinide attenuates lipopolysaccharide (LPS)-induced blood-brain barrier (BBB) and depressive-like behavior in mice by targeting Nrf-2 signaling
Yuan et al. Protective effect of resveratrol on kidney in rats with diabetic nephropathy and its effect on endoplasmic reticulum stress.
Ahn et al. Hepatoprotective effects of Lycium chinense Miller fruit and its constituent betaine in CCl4-induced hepatic damage in rats
Park et al. Narirutin fraction from citrus peels attenuates alcoholic liver disease in mice
Zhang et al. Urolithin A, a pomegranate metabolite, protects pancreatic β cells from apoptosis by activating autophagy
Yan et al. Panax notoginsenoside saponins Rb1 regulates the expressions of Akt/mTOR/PTEN signals in the hippocampus after focal cerebral ischemia in rats
Sun et al. Baicalin and N-acetylcysteine regulate choline metabolism via TFAM to attenuate cadmium-induced liver fibrosis
Wang et al. 6′-O-Caffeoylarbutin from Que Zui tea ameliorates acetaminophen-induced liver injury via enhancing antioxidant ability and regulating the PI3K signaling pathway
Zhou et al. Schisandrin B inhibits inflammation and ferroptosis in S. aureus-induced mastitis through regulating SIRT1/p53/SLC7A11 signaling pathway
Hu et al. Nicotinic acid against acetaminophen-induced hepatotoxicity via Sirt1/Nrf2 antioxidative pathway in mice
WO2016026139A1 (zh) 用于治疗非酒精性脂肪肝疾病的药物及应用
Rodniem et al. Protective effect of alpha-mangostin on thioacetamide-induced liver fibrosis in rats as revealed by morpho-functional analysis
Zhao et al. Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
Sun et al. Gastroprotective effect of fucoidan from Sargassum siliquastrum against ethanol-induced gastric mucosal injury
CN118178446A (zh) 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用
Rong et al. Melatonin: a novel strategy for prevention of obesity and fat accumulation in peripheral organs through the improvements of circadian rhythms and antioxidative capacity
Chen et al. Gypensapogenin I alleviates PANoptosis, ferroptosis, and oxidative stress in myocardial ischemic–reperfusion injury by targeting the NOX2/AMPK pathway
TWI634886B (zh) Compound composition for liver-free side effects with reduced liver fat for treating symptoms of non-alcoholic fatty liver disease (NAFLD)
HK40089284A (zh) 预防或治疗脂肪肝的药物组合物
Guo et al. Inhibitory effect of aqueous extract of Scrophularia ningpoensis on β-cell pyroptosis in diabetic mice
KR20220002047A (ko) 지페노사이드 화합물을 포함하는 간 질환 예방 또는 치료용 조성물
Cominguez et al. Clitorin, a Flavonoid Compound of Papaya, Ameliorates Non-Alcoholic Fatty Liver Disease in Western Diet-induced Mice and Oleic Acid-induced HepG2 Cells